In human AAA specimens, the gene expression of PPARGC1A was reduced by 51%, and the gene expression levels of VDAC and TFAM were reduced significantly concomitant with the PPARGC1A expression compared to the healthy control [49]. This evidence concerns the gene PPARGC1A and triple-A syndrome.